Prostate Cancer Clinical Trial
Official title:
Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early
detection and improved local therapies a large number of men will be cured. The clinical
needs include early detection, accurate initial staging and detection of local recurrence or
metastases in order to permit application of the most appropriate therapy. Therapeutic
monitoring and prognostic assessment are equally important. Imaging can play an important and
crucial role in meeting these clinical needs.
Positron emission tomography (PET) imaging has gained an important role in the clinical
management of cancer patients. 18F-DCFBC is a novel low molecular weight prostate specific
membrane antigen (PSMA)-based radiopharmaceutical which is radiolabeled with a fluorine-18
positron emitter for PET imaging. Preclinical mouse prostate cancer tumor model imaging
studies of 18F-DCFBC demonstrate high specific uptake in PSMA expressing prostate cancer
cells. The investigators will assess the hypothesis that 18F-DCFBC, a new positron emission
tomography (PET) radiopharmaceutical may possess pharmacokinetic and pharmacodynamic
properties that will represent an advance in imaging prostate cancer. This initial phase I
study will determine the biodistribution, pharmacokinetics, and prostate specific tumor
uptake in patients with metastatic prostate cancer.
Prostate cancer is the most common cancer among men in the United States. Through early
detection and improved local therapies a large number of men will be cured. The clinical
needs include early detection, accurate initial staging and detection of local recurrence or
metastases in order to permit application of the most appropriate therapy. Therapeutic
monitoring and prognostic assessment are equally important. Imaging can play an important and
crucial role in meeting these clinical needs.
Positron emission tomography (PET) imaging has gained an important role in the clinical
management of cancer patients. 18F-DCFBC is a novel low molecular weight prostate specific
membrane antigen (PSMA)-based radiopharmaceutical which is radiolabeled with a fluorine-18
positron emitter for PET imaging. Preclinical mouse prostate cancer tumor model imaging
studies of 18F-DCFBC demonstrate high specific uptake in PSMA expressing prostate cancer
cells. The investigators will assess the hypothesis that 18F-DCFBC, a new positron emission
tomography (PET) radiopharmaceutical may possess pharmacokinetic and pharmacodynamic
properties that will represent an advance in imaging prostate cancer. This initial phase I
study will determine the biodistribution, pharmacokinetics, and prostate specific tumor
uptake in patients with metastatic prostate cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |